PRCT at a glance
PROCEPT BioRobotics Corp (PRCT, SEC CIK 1588978) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on October 2, 2026 and Form 4 insider filings as recently as October 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), PROCEPT BioRobotics Corp (PRCT) reported revenue of $308.1 million (up 37.2% from FY2024) and a net loss of $95.6 million. Diluted EPS was -$1.72.
- As of June 30, 2026, 29 institutional investment managers tracked by SignalX reported holding PROCEPT BioRobotics Corp (PRCT) shares worth $432.6 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Nouri Alaleh on September 9, 2026 of 297 shares at $20.95 per share.
- In the last 90 days, PRCT insiders reported 1 open-market purchase ($498K) and 3 open-market sales ($22K) on Form 4, a net purchase of $476K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $308.1M
- +37.2% vs prior year
- Insiders · 90 days
- 1 buy · 3 sells
- Net +$476K
- 13F holders
- 29 funds
- $432.6M · +2 vs prior quarter
- Latest 8-K
- Sep 24, 2026
- Item 1.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Develops and sells AquaBeam and HYDROS robotic systems for minimally invasive urologic surgery focused on benign prostatic hyperplasia (BPH) treatment
- New emphasis on prostate cancer treatment with ongoing clinical trials including the pivotal WATER IV PCa randomized FDA-approved IDE study
- Strategic shift toward global expansion and increased efforts in private payor coverage and direct-to-patient marketing beyond urologists
- Install base growth to 912 robotic systems globally as of Dec 31, 2025, up from prior years, with revenue rising to $308.1 million in 2025
- Notable investment in AI and machine learning to improve treatment planning and product scalability for future innovation
Risk Factors
- FDA regulatory risk: ongoing need to comply with FDA requirements for marketing approval and labeling limitations affecting product acceptance
- Macroeconomic exposure: sales dependent on U.S. hospital and surgeon adoption, limited international presence, market growth constrained by reimbursement variability
- Supply chain risk: reliance on third-party distributors and suppliers for timely product components and distribution in targeted markets
- Market disruption threat: competition from established surgical alternatives and emerging robotic or medical technologies impacting surgeon and hospital adoption
- Financial risk: $52M term loan with restrictive covenants and $286.5M cash on hand with $641.6M accumulated deficit, risking liquidity if covenants breached or capital markets tighten
Management Discussion & Analysis
- Revenue $308.1M, up 37% YoY from $224.5M; system sales up $15.8M (18%), hand-piece sales up $60.0M (49%)
- Gross margin 64% vs 61% YoY, cost of sales up 28% to $111.8M driven by higher volume and warranty costs
- Best segment: hand-pieces with $181.4M revenue, worst: systems at $106.1M; service revenue $20.5M up 61%
- Operating expenses up 28% to $300.1M; R&D $71.3M (+14%), SG&A $228.8M (+33%) due to sales/marketing expansion
- Net loss $95.6M vs $91.4M; operating loss $103.9M vs $96.6M; interest expense down 14% to $3.6M; net interest/income up 24% to $12.1M
- Cash $286.5M, loan outstanding $52.0M; net cash used in operating activities $49.0M; financing inflow $11.2M from stock and ESPP
- Management expects continued revenue growth from expanding robotic install base and system utilization, investing in R&D and sales infrastructure
- Risks: reimbursement coverage, cost management, regulatory approval, market competition, and funding needs remain key uncertainties
AI summary of the PRCT 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $94.5M, up 19% YoY from $79.2M
- Gross margin 66% vs 65% YoY, including a $2.9M one-time tariff refund
- Best line: system sales and leases $32.5M, up 30% YoY
- Net cash used in operations $57.4M vs $32.0M; cash and equivalents $227.9M
- Outlook: cash and anticipated revenue expected to fund operations through at least next twelve months
Risk Factors
- No material risk-factor changes during six months ended June 30, 2026
- Carried-forward healthcare-industry and company-specific risks from December 31, 2025 10-K
- Unknown or currently immaterial risks could materially affect business, cash flows, or results
- Historical financial performance not reliable for forecasting future results or trends
AI summary of the PRCT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- CIBC term-loan maturity extended 12 months, from October 1, 2027 to October 1, 2028
- Added financing runway reduces near-term refinancing pressure
Item 2.02: Results of Operations and Financial Condition
- Q2 FY2026 results for quarter ended June 30, 2026, announced August 4, 2026
- Full financial results furnished in Exhibit 99.1, requiring review for revenue, profitability, and guidance
AI summaries of PRCT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PRCT
Don't miss the next PRCT filing
- Alerts as it files. A push when PRCT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PRCT, by share count.
- Ask anything. An AI agent that reads every PRCT filing and answers with sources.
PRCT alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Mack Michael | A | Oct 2, 2026 | 12,191 | - |
| Mack Michael | A | Oct 2, 2026 | 7,727 | - |
| Nouri Alaleh | Sell | Sep 9, 2026 | 297 | $20.95 |
| Waters Kevin | Sell | Sep 9, 2026 | 373 | $20.95 |
| Templin Barry L | Sell | Sep 9, 2026 | 373 | $20.95 |
| Waters Kevin | A | Aug 13, 2026 | 29,527 | - |
| Nouri Alaleh | A | Aug 13, 2026 | 31,773 | - |
| Waters Kevin | A | Aug 13, 2026 | 40,851 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $224.5M | $308.1M |
| Gross Profit | - | $137.1M | $196.2M |
| Operating Income | - | -$96.6M | -$103.9M |
| Net Income | - | -$91.4M | -$95.6M |
| Gross Margin | - | 61.1% | 63.7% |
| Op. Margin | - | -43.0% | -33.7% |
| Net Margin | - | -40.7% | -31.0% |
| Balance Sheet | |||
| Total Assets | $404.7M | $534.0M | $508.1M |
| Equity | $280.8M | $402.2M | $365.9M |
| ROE | - | -22.7% | -26.1% |
| Per Share | |||
| EPS | - | $-1.75 | $-1.72 |
| Cash Flow | |||
| Operating CF | - | -$99.2M | -$49.0M |
| CapEx | - | $4.4M | $9.4M |
Source: XBRL data in PROCEPT BioRobotics Corp (PRCT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate PRCT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 29 | $432.6M |
| Q1 2026 | 27 | $456.5M |
| Q4 2025 | 25 | $649.6M |
| Q3 2025 | 26 | $872.4M |
| Q2 2025 | 28 | $1.44B |
| Q1 2025 | 26 | $1.22B |
| Q4 2024 | 22 | $1.55B |
| Q3 2024 | 19 | $358.1M |
- T. Rowe Price Group+726.5K (+120%)
- BlackRock+507.8K (+12%)
- Goldman Sachs Group+145.5K (+48%)
- AQR Capital Management+114.6K (+45%)
- Vanguard Portfolio Management LLC+105.4K (+4%)
- Millennium Management−381.1K (-38%)
- Morgan Stanley−372.0K (-38%)
- Two Sigma Investments−177.5K (-78%)
- Bank of America Corp−114.5K (-18%)
- FMR LLC (Fidelity)−17.0K (-1%)
- Dimensional Fund Advisors+36.5K
- Raymond James Financial+15.3K
- Citadel Advisors LLC+12.6K
- Renaissance Technologies LLC−116.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 202 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PRCT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 5, 2026 | - | - | - |
| 8-K | Oct 2, 2026 | - | - | - |
| 8-K | Sep 24, 2026 | - | Analysis | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
PRCT SEC filings: frequently asked questions
Are PRCT insiders buying or selling?
In the last 90 days, PROCEPT BioRobotics Corp (PRCT) officers, directors and 10% owners reported 1 open-market purchase worth $498,315 by 1 insider and 3 open-market sales worth $21,854 by 3 insiders on Form 4, a net purchase of $476,461. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold PRCT stock?
As of June 30, 2026, the largest PROCEPT BioRobotics Corp (PRCT) holders among the 13F filers tracked by SignalX were BlackRock ($110.0 million), Vanguard Portfolio Management LLC ($57.1 million), Vanguard Capital Management LLC ($55.6 million), State Street Corp ($36.5 million), FMR LLC (Fidelity) ($32.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was PRCT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), PROCEPT BioRobotics Corp (PRCT) reported revenue of $308.1 million (up 37.2% from FY2024) and a net loss of $95.6 million. Diluted EPS was -$1.72. The figures come from the XBRL data in the 10-K.
What are the main risks in PRCT's latest 10-K?
In the 10-K filed February 26, 2026, PROCEPT BioRobotics Corp (PRCT) flagged: FDA regulatory risk: ongoing need to comply with FDA requirements for marketing approval and labeling limitations affecting product acceptance. Macroeconomic exposure: sales dependent on U.S. hospital and surgeon adoption, limited international presence, market growth constrained by reimbursement variability. (AI summary of the Risk Factors section.)
What did PRCT report in its latest 8-K?
PROCEPT BioRobotics Corp (PRCT) filed an 8-K on September 24, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). CIBC term-loan maturity extended 12 months, from October 1, 2027 to October 1, 2028.
What are the latest PRCT SEC filings?
PROCEPT BioRobotics Corp (PRCT) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on October 2, 2026 and a Form 4 insider filing on October 5, 2026.
What is PRCT's SEC CIK number?
PROCEPT BioRobotics Corp (PRCT)'s SEC Central Index Key (CIK) is 1588978. EDGAR lists every PRCT filing under that number.
Ask anything about PRCT
The research agent reads PRCT's filings, financials, insider trades and 13F holders, then answers with sources.